Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

DOI Web Site 22 Citations
  • Geoffrey R. Oxnard
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Yuebi Hu
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Kathryn F. Mileham
    Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina
  • Hatim Husain
    Moores Cancer Center, University of California San Diego, La Jolla
  • Daniel B. Costa
    Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • Philip Tracy
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Nora Feeney
    Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Lynette M. Sholl
    Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
  • Suzanne E. Dahlberg
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Amanda J. Redig
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • David J. Kwiatkowski
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Michael S. Rabin
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Cloud P. Paweletz
    Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Kenneth S. Thress
    Translational Sciences, Oncology IMED Biotech Unit, AstraZeneca, Boston, Massachusetts
  • Pasi A. Jänne
    Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Journal

  • JAMA Oncology

    JAMA Oncology 4 (11), 1527-, 2018-11-01

    American Medical Association (AMA)

Citations (22)*help

See more

Details 詳細情報について

Report a problem

Back to top